Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
121 studies found for:    "Gout"
Show Display Options
Rank Status Study
21 Completed
Has Results
Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.
Condition: Gout
Interventions: Drug: Febuxostat;   Drug: Allopurinol;   Drug: Placebo
22 Completed Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout
Condition: Gout
Interventions: Drug: Placebo;   Drug: Allopurinol;   Drug: BCX4208
23 Active, not recruiting A Proof-of-Concept Study Of AC-201 to Prevent Gout Flares
Condition: Gout Flares
Interventions: Drug: AC-201 50mg Capsule BID for 16 Weeks;   Drug: Placebo Capsule BID for 16 Weeks
24 Completed Study Utilizing Rilonacept in Gout Exacerbations
Condition: Acute Gout Flare
Interventions: Drug: rilonacept;   Drug: indomethacin;   Other: placebo
25 Completed
Has Results
Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients
Condition: Acute Gout
Interventions: Drug: Canakinumab;   Drug: Triamcinolone acetonide
26 Active, not recruiting Evaluating the Effectiveness of a Chronic Disease Management Program for Gout
Condition: Recurrent or Tophaceous Gout
Interventions: Other: Control;   Other: Gout Disease Management Program
27 Completed PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1
Condition: Intercritical Gout
Intervention: Drug: rilonacept
28 Completed
Has Results
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.
Condition: Acute Gout
Interventions: Drug: Canakinumab 150 mg;   Drug: Triamcinolone acetonide 40 mg;   Drug: Placebo to canakinumab;   Drug: Placebo to triamcinolone acetonide
29 Completed
Has Results
Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients
Condition: Chronic Gout Refractory to Conventional Therapy
Intervention: Drug: pegloticase 8 mg i.v.
30 Completed
Has Results
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
Condition: Acute Gout
Interventions: Drug: Canakinumab 150 mg;   Drug: Triamcinolone acetonide 40 mg;   Drug: Placebo to canakinumab;   Drug: Placebo to triamcinolone acetonide
31 Completed Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)
Conditions: Moderate to Severe Gout;   Hyperuricemia
Interventions: Drug: Combination 400;   Drug: Allopurinol;   Drug: Combination 600
32 Active, not recruiting Arthritis Research UK Gout Treatment Trial - Phase 2
Condition: Gout
Interventions: Other: Nurse intervention;   Other: Standard care
33 Completed
Has Results
Long-Term Safety of Febuxostat in Subjects With Gout.
Condition: Gout
Intervention: Drug: Febuxostat
34 Not yet recruiting Colchicine Or Naproxen Treatment for ACute gouT
Condition: Gout
Interventions: Drug: Low-dose colchicine;   Drug: Naproxen
35 Completed
Has Results
Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout
Condition: Gout
Interventions: Drug: Placebo;   Drug: Febuxostat
36 Completed RDEA3170 Monotherapy in Subjects With Gout
Condition: Gout
Interventions: Drug: Placebo;   Drug: RDEA3170 5 mg;   Drug: RDEA3170 10 mg;   Drug: RDEA3170 12.5 mg
37 Completed Open-Label Lesinurad Monotherapy Extension Study in Gout
Condition: Gout
Intervention: Drug: lesinurad
38 Completed
Has Results
Febuxostat Versus Allopurinol Control Trial in Subjects With Gout
Condition: Gout
Interventions: Drug: Febuxostat;   Drug: Allopurinol
39 Completed
Has Results
MPC-004 for the Treatment of an Acute Gout Flare
Condition: Gout
Interventions: Drug: High Dose Colchicine  (4.8 mg total dose);   Drug: Low Dose Colchicine (1.8mg total dose);   Other: Placebo Control
40 Completed
Has Results
Efficacy and Safety of Oral Febuxostat in Participants With Gout
Condition: Gout
Interventions: Drug: Febuxostat;   Drug: Allopurinol

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years